Johnson & Johnson’s quiet pivot: drug price cuts and tariff relief signal a new era
Johnson & Johnson’s recent agreement with the Trump administration marks a key moment in U.S. drug pricing reform. By joining the TrumpRx platform and offering Medicaid pricing aligned with wealthy nations, the company gains tariff relief while promising significant price reductions. This deal signals a potential turning point in the complex balance between pharmaceutical profits, government policy, and patient access.